Logo do repositório
 
Publicação

Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review

2026-01-03Artigo de revisão Acesso aberto
Ver registo simples
dc.contributor.authorEuropean Headache Federation, EHF
dc.contributor.authorGil-Gouveia, Raquel
dc.date.accessioned2026-01-27T12:18:57Z
dc.date.available2026-01-27T12:18:57Z
dc.date.issued2026-01-03
dc.description.abstractObjective To evaluate the long-term safety (≥12months) of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) or its receptor in migraine prevention by synthesising evidence from clinical trials and real-world studies. We focus on drug discontinuation due to adverse events and the type and frequency of adverse events. This is the first review to analyse the effects of the long-term use of all anti-CGRP (receptor) mAbs, aiming to provide novel insights for clinical practice and future treatment strategies. Methods We systematically searched PubMed, Cochrane Library, and ClinicalTrials.gov for studies with ≥12months of anti-CGRP (receptor) mAb use between January 2013 and April 2025. A random-effects meta-analysis of proportions (logit transformation, inverse variance weighting, restricted maximum likelihood) was performed to estimate pooled discontinuation and adverse event rates. Risk of bias was assessed using the ROBINS-I score. Results From a total of 1,499 records, 14met the inclusion criteria and were eligible for data analysis. These 14 records corresponded to 11 individual studies with observational durations all exceeding 12months. Seven studies investigated erenumab, two eptinezumab, and one each fremanezumab and galcanezumab. All studies were judged to have a severe risk of bias due to their underlying design. The overall pooled proportion of treatment discontinuation for any reason among patients receiving anti-CGRP (receptor) mAbs was 23%, whereas the pooled proportion of discontinuation specifically due to adverse events was substantially lower at 3%. Time-trend analysis showed that adverse event–related discontinuation remained low (<5%) beyond the first year, while overall adverse event incidence was high at baseline (>70%) but did not further increase with prolonged follow-up. Conclusion Evidence on long-term use of anti-CGRP (receptor) mAbs over 12months remains limited, but our analysis indicates good tolerability with consistently low adverse event-related discontinuation, no emergent safety signals, and largely non-serious, stable adverse event profiles. However, heterogeneity and study-level bias warranteng
dc.identifier.citationEuropean Headache Federation, EHF (2026). Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review. The journal of headache and pain, 27(1), Article 10. https://doi.org/10.1186/s10194-025-02256-0
dc.identifier.doi10.1186/s10194-025-02256-0
dc.identifier.eid105027172652
dc.identifier.issn1129-2369
dc.identifier.othere0a391fc-8247-40e9-85ff-af01a172bc5c
dc.identifier.pmcPMC12776973
dc.identifier.pmid41484941
dc.identifier.urihttp://hdl.handle.net/10400.14/56772
dc.identifier.wos001656169300001
dc.language.isoeng
dc.peerreviewedyes
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCGRP
dc.subjectEptinezumab
dc.subjectErenumab
dc.subjectFremanezumab
dc.subjectGalcanezumab
dc.subjectLong-term safety
dc.subjectMigraine
dc.titleDecoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic revieweng
dc.typereview article
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.titleThe journal of headache and pain
oaire.citation.volume27
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
139074142.pdf
Tamanho:
4.4 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

CIIS - Livros e Partes de Livros / Books and Books Parts